Participated · Equity · Apr 2026

Oury Medical specializes in manufacturing orthopedic and spinal surgical instruments and implants and has grown through a series of targeted acquisitions since 2022. The group reports more than €25 million in revenue and employs nearly 200 people across five production sites following its latest acquisition of Céfiméca. Oury Medical’s recent fundraising of over €30 million was used to acquire Céfiméca and support planned industrial investments to optimize production. The company expanded rapidly from €5 million in revenue in 2022 to over €25 million by 2025, driven by acquisitions and investments in production and operational efficiency. Backed by Tag Partners (majority investor since 2022) and new investor Isalt (via the FST), Oury Medical intends to pursue further targeted purchases to consolidate its position on major global markets and aim to become a leading European player in orthopedics and spine surgery.

Led · Equity · Feb 2026

Founded in 2017 and based in Marcq-en-Baroeul near Lille, Meelo has built a Software-as-a-Service platform that screens and secures the financing path of customers for banks, lenders and other financial institutions. Using only a client’s email address and phone number, the software calculates the probability that the person is who they claim to be, thereby preventing fraud and streamlining digital onboarding. The company promises an interaction that is instant, secure and responsible, addressing a critical pain point in remote client acquisition. Meelo’s technology targets financial institutions that must meet stringent compliance and KYC requirements while keeping conversion rates high. With its latest funding, the firm plans to accelerate international expansion. Prior to the current round, Meelo raised €3 million in 2022, underscoring steady investor interest in its fraud-prevention capabilities.

Participated · Equity · Feb 2026

Founded in 2014, Paris-based DentalMonitoring has built an FDA De Novo-cleared, MDR-certified software-as-a-medical-device that lets orthodontists remotely track treatment progress through AI analysis of patient-submitted images. The system draws on a proprietary library of two billion intraoral images and is protected by more than 470 patents, giving it strong data and IP defensibility. Over two million patients have used the platform, and the company partners with appliance manufacturers, practice-management software vendors, and intraoral scanner providers to integrate its monitoring workflow across the orthodontic ecosystem. DentalMonitoring is treatment- and appliance-agnostic, positioning itself as an operating system layer for digital dental care. Having reached operational profitability in 2025, the company is now doubling down on innovation via a newly launched software development center focused on AI R&D. Near-term growth plans include deepening penetration in Europe, the U.S., Australia, and Japan while expanding into Brazil, Turkey, Southeast Asia, and the Middle East, as well as applying its AI technology to broader dental applications beyond orthodontics.

Participated · Series C · Feb 2024

Unseenlabs is a Rennes, France–based RF data and solutions provider focused on maritime domain awareness. Its core technology detects and geolocates radio frequency signals from space to identify and characterize vessels anywhere on the globe, at any time and in any weather. The company provides high‑added‑value data and solutions to help fight illegal activities at sea and to serve private‑sector segments. The recent €85M funding will be used to significantly expand observation capabilities through the launch of multiple satellites and to innovate and deploy new products and solutions. Unseenlabs also plans to strengthen its international presence, particularly in the American and Asian markets, and to consolidate activity within private‑sector areas such as oil and gas, insurance, shipowners, economic intelligence, and offshore energy. The company has accumulated €120M in total funding since inception and is led by CEO Clément Galic. Unseenlabs develops satellite-borne electromagnetic monitoring and intelligence used to observe maritime activity. Through its existing three orbiting satellites the company can track maritime traffic, particularly ships that have switched off their identification systems. The service targets hard-to-detect activity such as illegal fishing, smuggling and piracy, positioning the company as an "eyes in the sky" capability. The recent funding is intended to accelerate commercial growth and to further deploy the company's satellite constellation. Unseenlabs raised €20 million in a Series B. The company was founded in 2015 by Clement Galic and Jonathan Galic and is based in Rennes, France.

Participated · Series D · May 2023

TISSIUM is a clinical and commercial-stage MedTech company founded in 2013 that develops fully biosynthetic, biomorphic, programmable elastomeric polymers for atraumatic tissue repair and tissue reconstruction. The company’s first commercial product, COAPTIUM® CONNECT, received FDA marketing authorization and TISSIUM has entered the U.S. commercial market. Its diversified pipeline includes one commercial product and six products in development across three core verticals: atraumatic sutureless nerve repair, atraumatic hernia repair, and cardiovascular sealants. TISSIUM pairs its polymer solutions with specialized delivery and activation devices designed to optimize procedure consistency and usability. The company is based in Paris and Cambridge and operates a manufacturing site in Roncq, France. Recent financing provides capital to support commercial rollout, advance multiple clinical programs and continue expanding its proprietary biomorphic polymer platform.